GSK’s RSV Vaccine Shows Promise in Older Adults

GSK’s investigational respiratory syncytial virus (RSV) vaccine showed “clinically meaningful” efficacy in a phase 3 study that enrolled 25,000 older participants.

The company said that its RSV vaccine candidate showed statistically significant and clinically meaningful efficacy in adults who are 60 years and older. In addition, the effect was consistent across RSV A and RSV B strains and in those 70 years and older.

GSK plans on submitting applications to regulatory agencies later this year. RSV vaccines have yet to be approved by any regulatory agency.